Application of okannin and composition and collagenous fiber protector

Through Okanin and its compositions, the collagen synthesis and inhibit key signaling pathways are solved, and the protection of collagen fibers under photo damage is achieved, and effective protection of collagen fibers and skin aging is reduced.

CN118873518APending Publication Date: 2024-11-01SHENZHEN HUJIA TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410941313.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

The prior art has failed to effectively explore the application of Okanin in protecting collagen fibers, especially in the case of photodamage, how to protect collagen fibers through Okanin is still an unsolved problem.

Method used

Through Okanin and its compositions, collagen synthesis is promoted, matrix metalloproteinase expression is inhibited, TGF-β/Smad pathway is regulated, AP-1 and MAPK pathways are inhibited, thereby protecting light-damaged skin collagen fibers.

Benefits of technology

Effectively protect photodamaged collagen fibers, reduce skin aging, promote collagen synthesis and expression, reduce the destruction of matrix metalloproteinases, and significantly improve skin health.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118873518A_ABST
    Figure CN118873518A_ABST
Patent Text Reader

Abstract

The embodiment of the invention discloses application of okannin and a composition thereof and a collagenous fiber protector. The collagenous fiber protector can protect collagenous fibers and light-damaged skin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of occannin, and more specifically, to the use of occannin and its composition and collagen fiber protector. Background Art

[0002] Collagen fibers are a type of fiber composition containing collagen and amino acids, and are also an important component of tissues such as skin, sclera and tendons.

[0003] Collagen fibers are often damaged under light and turn into an aged state. At present, how to protect collagen fibers from being damaged by light is a research with great significance.

[0004] Although some research has been done on the protective mechanism of collagen fibers and corresponding results have been achieved, there are still many unknown areas in the protective mechanism of collagen fibers. For example, how to protect collagen fibers through okanin is an unresolved issue.

[0005] In the disclosed prior art, oxanide is used as an anti-tumor drug and antioxidant. Regarding its anti-tumor use, please refer to the records in Chinese patent publications such as CN117224512A and CN114895032A; regarding its use as an antioxidant, please refer to the records in Chinese patent publications such as CN109475472A, CN114340739A and CN116669688A.

[0006] In general, there is no research linking okananin to photodamaged collagen fibers. Therefore, how to protect photodamaged collagen fibers through okananin is an urgent problem to be solved. Summary of the invention

[0007] An object of embodiments of the present invention is to solve the above-mentioned problems and provide advantages which will be described later.

[0008] Another purpose of the embodiments of the present invention is to provide a use of okanin and a composition and a collagen fiber protector, which can protect collagen fibers and photodamaged skin.

[0009] To achieve the aforementioned objectives, the embodiments of the present application mainly provide the following technical solutions:

[0010] In one aspect, the present application embodiment provides a use of okanin in preparing a collagen fiber protector for photodamaged skin. Protecting photodamaged skin is achieved by protecting collagen fibers.

[0011] In some technical solutions, the collagen fiber protector for photo-damaged skin has the function of protecting collagen in photo-damaged skin; the purpose of protecting collagen fibers is achieved by protecting collagen.

[0012] In some technical schemes, when the collagen fiber protector for photo-damaged skin has the function of protecting collagen in photo-damaged skin, the collagen fiber protector for photo-damaged skin has at least one of the functions of promoting collagen synthesis in photo-damaged skin and inhibiting the expression of matrix metalloproteinases in photo-damaged skin.

[0013] The function of protecting collagen is achieved by promoting collagen synthesis in photodamaged skin and / or inhibiting the expression of matrix metalloproteinases in photodamaged skin.

[0014] In some technical schemes, when the collagen fiber protector for photodamaged skin has the function of promoting collagen synthesis, the collagen fiber protector for photodamaged skin has at least one of the function of promoting the mRNA expression of collagen genes in photodamaged skin and the function of promoting collagen synthesis in photodamaged skin based on the TGF-β / Smad pathway.

[0015] The function of promoting collagen synthesis in photodamaged skin is achieved by promoting mRNA expression of collagen genes in photodamaged skin and / or promoting collagen synthesis in photodamaged skin based on the TGF-β / Smad pathway.

[0016] In some technical schemes, when the collagen fiber protector of photodamaged skin has the function of inhibiting the expression of matrix metalloproteinases, the collagen fiber protector of photodamaged skin has at least one of the functions of inhibiting the expression of MMP-1 in photodamaged skin, inhibiting the expression of MMP-3 in photodamaged skin, and inhibiting the expression of MMP-9 in photodamaged skin.

[0017] The function of inhibiting the expression of matrix metalloproteinases is achieved by inhibiting the expression of at least one of MMP-1, MMP-3, and MMP-9 in light-damaged skin.

[0018] In some technical schemes, when the collagen fiber protector of photodamaged skin has at least one of the functions of inhibiting the expression of MMP-1 in photodamaged skin, inhibiting the expression of MMP-3 in photodamaged skin, and inhibiting the expression of MMP-9 in photodamaged skin, the collagen fiber protector of photodamaged skin has the function of inhibiting the expression of AP-1 in photodamaged skin.

[0019] By inhibiting the expression of AP-1 in photodamaged skin, at least one of the following functions is achieved: inhibiting the expression of MMP-1 in photodamaged skin, inhibiting the expression of MMP-3 in photodamaged skin, and inhibiting the expression of MMP-9 in photodamaged skin.

[0020] In some technical schemes, when the collagen fiber protector for photodamaged skin has the function of promoting the mRNA expression of collagen genes in photodamaged skin, the collagen genes include at least one of COL1A1, COL3A1, COL5A1, COL6A1, and COL7A1.

[0021] In some technical schemes, when the collagen fiber protector for photodamaged skin has the function of promoting the mRNA expression of collagen genes in photodamaged skin, the collagen fiber protector for photodamaged skin has the function of promoting the mRNA expression of at least one collagen gene among type I collagen, type III collagen, type V collagen, type VI collagen and type VII collagen.

[0022] The function of promoting the mRNA expression of collagen genes in photodamaged skin is achieved by promoting the mRNA expression of at least one collagen gene among type I collagen, type III collagen, type V collagen, type VI collagen and type VII collagen.

[0023] In some technical schemes, when the collagen fiber protector for photodamaged skin has the function of promoting collagen synthesis in photodamaged skin based on the TGF-β / Smad pathway, the collagen fiber protector for photodamaged skin has at least one of the functions of promoting the expression of TGF-β, promoting the expression of Smad2 / 3 and inhibiting the expression of Smad7.

[0024] The function of promoting collagen synthesis in photodamaged skin based on the TGF-β / Smad pathway is achieved by promoting at least one of the expression of TGF-β, promoting the expression of Smad2 / 3 and inhibiting the expression of Smad7.

[0025] In some technical schemes, when the collagen fiber protector of photo-damaged skin has the function of inhibiting the expression of AP-1 in photo-damaged skin, the collagen fiber protector of photo-damaged skin has at least one of the functions of inhibiting the expression of c-FOS in photo-damaged skin and inhibiting the expression of c-JUN in photo-damaged skin.

[0026] The function of inhibiting the expression of AP-1 in photo-damaged skin is achieved by inhibiting at least one of the expression of c-FOS in photo-damaged skin and the expression of c-JUN in photo-damaged skin.

[0027] In some technical schemes, when the collagen fiber protector of photo-damaged skin has at least one of the functions of inhibiting the expression of c-FOS in photo-damaged skin and inhibiting the expression of c-JUN in photo-damaged skin, the collagen fiber protector of photo-damaged skin has the function of inhibiting the expression of MAPK in photo-damaged skin.

[0028] By inhibiting the expression of MAPK in photo-damaged skin, at least one of the functions of inhibiting the expression of c-FOS in photo-damaged skin and inhibiting the expression of c-JUN in photo-damaged skin is achieved.

[0029] In some technical schemes, when the collagen fiber protector of photodamaged skin has the function of inhibiting the expression of MAPK in photodamaged skin, the collagen fiber protector of photodamaged skin has the function of inhibiting at least one of the expression of JNK in photodamaged skin, the expression of p38 in photodamaged skin and the expression of ERK in photodamaged skin.

[0030] The function of inhibiting the expression of MAPK in photo-damaged skin is achieved by inhibiting at least one of the expression of JNK in photo-damaged skin, the expression of p38 in photo-damaged skin and the expression of ERK in photo-damaged skin.

[0031] In some technical solutions, the mass content of okanin is 0.01-5%.

[0032] In another aspect, the embodiment of the present application provides a collagen fiber protector for photodamaged skin, comprising okanin. Optionally, the mass content of okanin is 0.01-5%.

[0033] In another aspect, an embodiment of the present application provides a use of okanin in the preparation of a collagen synthesis promoter for photo-damaged skin.

[0034] In another aspect, an embodiment of the present application provides a use of okanin in preparing an mRNA expression promoter of collagen genes in photo-damaged skin.

[0035] In another aspect, an embodiment of the present application provides a use of okanin in the preparation of at least one of a type I collagen synthesis promoter, a type III collagen synthesis promoter, a type V collagen synthesis promoter, a type VI collagen synthesis promoter, and a type VII collagen synthesis promoter for photodamaged skin.

[0036] In another aspect, an embodiment of the present application provides a use of okanin in the preparation of a promoter for regulating collagen synthesis in photodamaged skin based on the TGF-β / Smad pathway.

[0037] In another aspect, an embodiment of the present application provides a use of okanin in the preparation of a TGF-β expression promoter for photodamaged skin.

[0038] In another aspect, an embodiment of the present application provides a use of okanine in preparing a Smad3 expression promoter for photodamaged skin.

[0039] In another aspect, the embodiments of the present application also provide a use of okanine in preparing a Smad7 expression inhibitor for photodamaged skin.

[0040] In another aspect, an embodiment of the present application provides a use of okanin in preparing an inhibitor of matrix metalloproteinase expression in photodamaged skin.

[0041] In another aspect, an embodiment of the present application provides a use of okanin in the preparation of at least one of an MMP-1 expression inhibitor, an MMP-3 expression inhibitor, and an MMP-9 expression inhibitor for photodamaged skin.

[0042] In another aspect, the embodiments of the present application provide a use of okanin in preparing an inhibitor of AP-1 expression in photodamaged skin.

[0043] In another aspect, an embodiment of the present application provides a use of okanin in preparing a c-FOS expression inhibitor for photodamaged skin.

[0044] In another aspect, an embodiment of the present application provides a use of okanin in preparing a c-JUN expression inhibitor for photodamaged skin.

[0045] In another aspect, the embodiments of the present application also provide a use of okanin in preparing a MAPK expression inhibitor for photodamaged skin.

[0046] In another aspect, an embodiment of the present application provides a use of okanin in the preparation of at least one of a JNK expression inhibitor, a p38 expression inhibitor, and an ERK expression inhibitor for photodamaged skin.

[0047] In another aspect, the use of an okanin-containing composition as a protector of collagen fibers in photodamaged skin.

[0048] The beneficial effects that can be achieved by the embodiments of the present application include:

[0049] In some embodiments, the use of okanine provided in accordance with the present application can protect collagen fibers in photodamaged skin, thereby effectively protecting the skin.

[0050] In some embodiments, the use of okanine provided in accordance with the present application can protect collagen in photodamaged skin, thereby effectively protecting collagen fibers and skin.

[0051] In some embodiments, the collagen fiber protector for photodamaged skin provided according to the implementation of the present application can protect the collagen fibers of photodamaged skin, thereby effectively protecting the skin.

[0052] In some embodiments, the use of the composition containing okanine provided in accordance with the present application can protect collagen fibers of photodamaged skin, thereby effectively protecting the skin.

[0053] Other advantages, objectives and features of the present invention will be embodied in part through the following description, and in part will be understood by those skilled in the art through study and practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0054] Figure 1 This is a HE-stained section image of mouse skin tissue in groups C, P, UV, N, L and M in the examples of the present application;

[0055] Figure 2 This is a HE-stained section image of the skin tissue of the H group of mice in the example of the present application;

[0056] Figure 3 A comparative schematic diagram of the epidermal thickness of the mouse skin in each group in the examples of the present application;

[0057] Figure 4 A comparative schematic diagram of the dermal thickness of the mouse skin in each group in the examples of the present application;

[0058] Figure 5 A Masson-stained section image of mouse skin tissue in groups C, P, UV, N, L and M in the examples of the present application;

[0059] Figure 6 A Masson-stained section image of mouse skin tissue in groups L, M and H in the example of the present application;

[0060] Figure 7 A comparative schematic diagram of the collagen content (Collagen ratio) in the skin tissue of each group of mice in the examples of the present application;

[0061] Figure 8 A schematic diagram showing a comparison of the content of collagen I in the skin tissue of each group of mice in the examples of the present application;

[0062] Fig. 9 A schematic diagram showing a comparison of the content of collagen III in the skin tissue of each group of mice in the examples of the present application;

[0063] Fig.10 A comparative schematic diagram of hydroxyproline (HYP) in the skin tissues of mice in each group in the examples of the present application;

[0064] Fig.11 A schematic diagram of the relative mRNA expression level of COL1A1 in each experimental group (C, P, UV, N, L, M and H groups) in the examples of the present application;

[0065] Fig.12 A schematic diagram of the relative mRNA expression level of COL2A1 in each experimental group (C, P, UV, N, L, M and H groups) in the examples of the present application;

[0066] Fig.13 A schematic diagram of the relative mRNA expression level of COL5A2 in each experimental group (C, P, UV, N, L, M and H groups) in the examples of the present application;

[0067] Fig.14 A schematic diagram of the relative mRNA expression level of COL6A1 in each experimental group (C, P, UV, N, L, M and H groups) in the examples of the present application;

[0068] Fig.15 A schematic diagram of the relative mRNA expression level of COL7A1 in each experimental group (C, P, UV, N, L, M and H groups) in the examples of the present application;

[0069] Fig.16 A schematic diagram of a protein band corresponding to TGF-β, Smads7 and Smads2 / 3 in the skin tissue of each group of mice in the examples of the present application;

[0070] Fig.17 A schematic diagram of the relative mRNA expression levels (Relative mRNA expression) of TGF-β, Smads7 and Smads2 / 3 in the skin tissues of each group of mice in the examples of the present application;

[0071] Fig.18 A schematic diagram of a protein band corresponding to MMP-1, MMP-3 and MMP-9 in the skin tissue of each group of mice in the examples of the present application;

[0072] Fig.19A schematic diagram of the relative protein content (Relative protein expression) of MMP-1, MMP-3 and MMP-9 in the skin tissue of each group of mice in the examples of the present application;

[0073] Fig. 20 A schematic diagram of a protein band corresponding to c-FOS and c-JUN in the skin tissue of each group of mice in the examples of this application;

[0074] Fig.21 A schematic diagram of the relative protein content (Relative protein expression) of c-FOS and c-JUN in the skin tissue of each group of mice in the examples of the present application;

[0075] Fig. 22 A schematic diagram of a protein band corresponding to p-JNK, JNK, p-ERK, ERK, p-P38, and P38 in the skin tissue of each group of mice in the examples of the present application;

[0076] Fig.23 Schematic diagram of the relative protein expression of p-JNK, JNK, p-ERK, ERK, p-P38, and P38 in the skin tissues of each group of mice in the examples of the present application. DETAILED DESCRIPTION

[0077] The present invention is further described in detail below in conjunction with the accompanying drawings so that those skilled in the art can implement the invention with reference to the description.

[0078] The terms "include", "comprising", "containing", "having" and any variations thereof in the embodiments of the present application are intended to cover non-exclusive inclusions. For example, a process, method, system, product or device comprising a series of steps or units is not limited to the listed steps or units, but may optionally include steps or units not listed, or may optionally include other steps or units inherent to these processes, methods, products or devices.

[0079] In addition to the above, it is still necessary to emphasize that the reference to "embodiment", "implementation method", etc. in this document means that the specific features, structures or characteristics described in conjunction with the embodiment may be included in at least one embodiment of the present application. The appearance of the phrase in various places in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It is explicitly and implicitly understood by those skilled in the art that the embodiments described herein may be combined with other embodiments.

[0080] Collagen is the most abundant protein in mammals, so unless otherwise specified, in the examples of this application, the term "collagen" can be used interchangeably with "collagen protein". Similarly, the term "collagen gene" can be used interchangeably with "collagen protein gene".

[0081] <Use of Okanin in the preparation of collagen fiber protectors for photodamaged skin>

[0082] Collagen fibers are an important component of the skin. When exposed to light, collagen fibers become disordered and broken, causing skin aging and damage.

[0083] The examples of the present application found that okanin and compositions containing okanin have the purpose of protecting collagen fibers. Therefore, the examples of the present application provide a use of okanin in preparing a collagen fiber protector for photodamaged skin, thereby effectively repairing skin damage. Exemplarily, okanin or a composition containing okanin can be used as a collagen fiber protector for photodamaged skin.

[0084] Collagen fibers are fiber compositions mainly containing collagen, glycine, proline, hydroxyproline, etc. Therefore, there are undoubtedly many ways to protect collagen fibers in photodamaged skin. Without creative efforts, it is impossible to determine certain specific protection paths.

[0085] Fortunately, in further research, the present application examples found that okanin can protect collagen fibers from the aspect of protecting collagen. It is understandable that a composition containing okanin, such as a collagen fiber protector for photodamaged skin, has the function of protecting collagen and can be used as a collagen protector for photodamaged skin.

[0086] Furthermore, Okanin's collagen-based protective approach for collagen fibers in photodamaged skin can also be achieved based on multiple different aspects, such as: promoting collagen synthesis, protecting collagen in photodamaged skin based on the MAPK pathway, etc.; see the detailed explanation below for details.

[0087] <Uses of Okanin in promoting collagen synthesis>

[0088] Collagen is the main component of collagen fibers and an important component of the skin.

[0089] From the perspective of promoting collagen synthesis, the present application embodiment also provides a use of okanin in preparing a collagen synthesis promoter for photodamaged skin. Therefore, the composition containing okanin can also be directly used to promote collagen synthesis in photodamaged skin or to prepare a collagen synthesis promoter for photodamaged skin.

[0090] It is understandable that the aforementioned collagen fiber protector of photo-damaged skin also has the function of promoting collagen synthesis.

[0091] There are also many ways to promote collagen synthesis. In further research, the embodiments of the present application found based on experimental verification that okanin can be used to directly upregulate the mRNA expression of various collagen synthesis-related genes to promote collagen synthesis, and can also regulate collagen synthesis in photodamaged skin through the TGF-β / Smad pathway, etc.; see the detailed explanation below for details.

[0092] <Use of Okanin to upregulate the mRNA expression level of collagen genes to promote collagen synthesis>

[0093] The examples of the present application also found that oxanin can be used to directly up-regulate the expression of mRNA of collagen genes (specifically referring to genes related to collagen synthesis, i.e., collagen synthesis genes) in photo-damaged skin to promote collagen synthesis; it is easy to understand that the composition containing oxanin also has the function of up-regulating the expression of mRNA of collagen genes in photo-damaged skin.

[0094] Therefore, an embodiment of the present application also provides a use of okanin in preparing an mRNA expression promoter of collagen genes in photo-damaged skin.

[0095] Collagen mainly includes type I, type III, type V, type VI and type VII collagen; among them, type I collagen and type III collagen are the two most abundant structural proteins in human skin, accounting for 80-85% and 10-15% of the total volume of the skin respectively.

[0096] In further research, the examples of the present application have experimentally verified that oxanin promotes the synthesis of types I, III, V, VI and VII collagen. Therefore, the examples of the present application also provide the following further uses of oxanin.

[0097] In some embodiments, the present application also provides a use of okanin in preparing a type I collagen synthesis promoter for photodamaged skin. It is understandable that the composition containing okanin also has the function of promoting type I collagen synthesis and can be used as a type I collagen synthesis promoter.

[0098] More specifically, in at least one embodiment, the composition containing okanin also has the function of promoting the expression of the COL1A1 gene of type I collagen α1 (type I collagen α1 chain) in photodamaged skin, and can promote type I collagen synthesis by upregulating the expression of the COL1A1 gene.

[0099] Therefore, it can be understood that, in at least one embodiment, the examples of the present application also provide a use of okanin in the preparation of an expression promoter of the COL1A1 gene for photodamaged skin, thereby promoting the synthesis of type I collagen.

[0100] In some embodiments, the present application also provides a use of okanin in preparing a type III collagen synthesis promoter for photodamaged skin. It is understandable that the composition containing okanin also has the function of promoting type III collagen synthesis and can be used as a type III collagen synthesis promoter.

[0101] More specifically, in at least one embodiment, the composition containing okanin also has the function of promoting the expression of the COL3A1 gene of type III collagen α1 (type III collagen α1 chain) in photodamaged skin, and can promote type III collagen synthesis by upregulating the expression of the COL3A1 gene.

[0102] Therefore, it can be understood that, in at least one embodiment, the examples of the present application also provide a use of okanin in the preparation of an expression promoter of the COL3A1 gene for photodamaged skin, thereby promoting the synthesis of type III collagen.

[0103] In some embodiments, the present application also provides a use of okanin in preparing a type V collagen synthesis promoter for photodamaged skin. It is understandable that the composition containing okanin also has the function of promoting type V collagen synthesis and can be used as a type V collagen synthesis promoter.

[0104] More specifically, in at least one embodiment, the composition containing okanin also has the function of promoting the expression of the COL5A2 gene of type V collagen α2 (type V collagen α2 chain), and can promote the synthesis of type V collagen by upregulating the expression of the COL5A2 gene.

[0105] Therefore, it can be understood that, in at least one embodiment, the examples of the present application also provide a use of okanin in the preparation of an expression promoter of the COL5A2 gene for photodamaged skin, thereby promoting the synthesis of type V collagen.

[0106] In some embodiments, the present application provides a use of okanin in preparing a type VI collagen synthesis promoter for photodamaged skin. It is understandable that the composition containing okanin also has the function of promoting type VI collagen synthesis and can be used as a type VI collagen synthesis promoter.

[0107] More specifically, in at least one embodiment, the composition containing okanin also has the function of promoting the expression of the COL6A1 gene of type VI collagen α1 (type VI collagen α1 chain), and can promote the synthesis of type VI collagen by upregulating the expression of the COL6A1 gene.

[0108] Therefore, it can be understood that, in at least one embodiment, the examples of the present application also provide a use of okanin in the preparation of an expression promoter of the COL6A1 gene for photodamaged skin, thereby promoting the synthesis of type VI collagen.

[0109] In some embodiments, the present application provides a use of okanin in preparing a type VII collagen synthesis promoter for photodamaged skin. It is understandable that the composition containing okanin also has the function of promoting type VII collagen synthesis and can be used as a type VII collagen synthesis promoter.

[0110] More specifically, in at least one embodiment, the composition containing okanine also has the function of promoting the expression of the COL7A1 gene of type VII collagen α1 (type VII collagen α1 chain), and can promote the synthesis of type VII collagen by upregulating the expression of the COL7A1 gene.

[0111] Therefore, it can be understood that, in at least one embodiment, the examples of the present application also provide a use of okanin in the preparation of an expression promoter of the COL7A1 gene for photodamaged skin, thereby promoting the synthesis of type VII collagen.

[0112] <Use of Okanin to Promote Collagen Synthesis by Modulating TGF-β / Smad Pathway>

[0113] The TGF-β / Smad pathway is the main signal transduction pathway that regulates the expression of collagen synthesis genes in the skin. After ultraviolet irradiation, skin tissue produces excessive ROS (reactive oxygen species), which leads to downregulation of the expression of TGF-β (transforming growth factor-β) and Smad2 / 3 (including Smad2 and Smad3) and upregulation of Smad7, thereby disrupting collagen synthesis.

[0114] Regarding Smad2, Smad3, and Smad7, the Smads family is an important gene family in the signal transduction pathway of transforming growth factor TGF-β. SMAD2 belongs to a receptor-activated SMADs. Smad3 is a key signal transduction molecule in the TGF-β / Smad signaling pathway, involved in regulating biological processes such as cell growth, differentiation, and disease development. Smad7 is a molecule involved in intracellular signal transduction of the transforming growth factor β (TGF-β) superfamily.

[0115] The examples of the present application also found that for photodamaged skin caused by UVB irradiation, okanin and compositions containing okanin can be used to promote the synthesis of skin collagen in photodamaged skin by regulating the TGF-β-Smad pathway, thereby alleviating the symptoms of skin photoaging caused by UVB irradiation. It is understandable that compositions containing okanin, such as the aforementioned collagen fiber protector for photodamaged skin, also have the function of promoting collagen synthesis in photodamaged skin based on the TGF-β / Smad pathway. Therefore, the examples of the present application also provide a use of okanin in the preparation of a promoter for regulating collagen synthesis in photodamaged skin based on the TGF-β / Smad pathway.

[0116] More specifically, in some embodiments, okanin and compositions containing okanin can be used to up-regulate the expression level of TGF-β to avoid destroying the synthesis of collagen, thereby promoting collagen synthesis. That is, compositions containing okanin, such as the aforementioned collagen fiber protector for photo-damaged skin, also have the function of up-regulating the expression level of TGF-β. Therefore, the embodiments of the present application also provide a use of okanin in the preparation of a TGF-β expression promoter for photo-damaged skin. The TGF-β expression promoter containing okanin can promote the synthesis of collagen in photo-damaged skin by up-regulating the expression level of TGF-β, thereby regulating the TGF-β-Smad pathway and alleviating the symptoms of skin photoaging caused by UVB irradiation.

[0117] In other embodiments, okanin and compositions containing okanin can be used to upregulate the expression level of Smad2 / 3 to avoid destroying the synthesis of collagen, thereby promoting collagen synthesis. That is, compositions containing okanin, such as the aforementioned collagen fiber protector for photodamaged skin, also have the function of upregulating the expression level of Smad2 / 3. Therefore, an embodiment of the present application provides a use of okanin in the preparation of a Smad2 / 3 expression promoter for photodamaged skin, which can promote the synthesis of collagen in photodamaged skin by upregulating the expression level of Smad2 / 3, thereby regulating the TGF-β-Smad pathway and alleviating the symptoms of skin photoaging caused by UVB irradiation.

[0118] In at least one embodiment, okanin and compositions containing okanin can be used to down-regulate the expression level of Smad7 to avoid destroying the synthesis of collagen, thereby promoting collagen synthesis. That is, compositions containing okanin, such as the aforementioned collagen fiber protector for photodamaged skin, also have the function of down-regulating the expression level of Smad7. Therefore, an embodiment of the present application also provides a use of okanin in the preparation of a Smad7 expression inhibitor for photodamaged skin, which can promote the synthesis of collagen in photodamaged skin by down-regulating the expression level of Smad7, thereby regulating the TGF-β-Smad pathway and alleviating the symptoms of skin photoaging caused by UVB irradiation.

[0119] <Use of Okanin to Protect Collagen by Regulating the Expression of Matrix Metalloproteinases>

[0120] The examples of the present application also found that oxanin and compositions containing oxanin can be used to inhibit the expression of matrix metalloproteinases (MMPs) in photodamaged skin, thereby reducing the damage of the matrix metalloproteinase family (MMPs) to collagen.

[0121] It is understandable that the composition containing okanin, such as the aforementioned collagen fiber protector for photodamaged skin, also has the function of inhibiting the expression of matrix metalloproteinases (MMPs) in photodamaged skin, reducing the damage to collagen, and achieving the protection of collagen, and therefore can be used as an inhibitor of the expression of matrix metalloproteinases for photodamaged skin. Therefore, the embodiment of the present application also provides a use of okanin in the preparation of an inhibitor of the expression of matrix metalloproteinases for photodamaged skin.

[0122] Optionally, the inhibitor of matrix metalloproteinase expression can be specifically used to inhibit the expression of at least one of MMP-1, MMP-3 and MMP-9. Among them, (1) MMP-1 is a multifunctional protein and the only MMP that can decompose intact fibrillar collagen. It can degrade type I and type III collagen fibers into specific fragments at a single site within the central triple helix, which are further hydrolyzed by other MMPs, ultimately damaging the collagen-rich dermis. (2) MMP-3 can degrade a large number of ECM proteins, such as type IV, type V, type IX and type X collagen, as well as gelatin, and activate other MMPs in the form of zymogens. (3) MMP-9, which is directly related to the increase in elastin and collagen synthesis, can digest type IV collagen, which is an important component of the skin basement membrane, which is responsible for the epidermal-dermal adhesion, which is essential for the integrity of the epidermis.

[0123] From the above, it can be seen that the composition containing okanin, such as the aforementioned matrix metalloproteinase expression inhibitor for photodamaged skin, also has the function of inhibiting the expression of at least one of MMP-1, MMP-3 and MMP-9, thereby achieving the inhibition of matrix metalloproteinase expression.

[0124] It is understandable that, in some embodiments, the matrix metalloproteinase expression inhibitor may also serve as at least one of a MMP-1 expression inhibitor, a MMP-3 expression inhibitor, and a MMP-9 expression inhibitor to inhibit the expression of matrix metalloproteinases.

[0125] It is to be understood that, in some embodiments, the embodiments of the present application also provide a use of okanin in the preparation of at least one of an MMP-1 expression inhibitor, an MMP-3 expression inhibitor, and an MMP-9 expression inhibitor for photodamaged skin.

[0126] <The role of ocannins in protecting collagen by regulating the AP-1 pathway>

[0127] AP-1 is a transcriptional activator in cells. It is a heterodimer composed of c-Fos and c-Jun and is an important factor affecting the expression of matrix metalloproteinases in the skin.

[0128] The AP-1 pathway can induce the synthesis of at least one member of the matrix metalloproteinase family (MMPs). Subsequently, the matrix metalloproteinase family (MMPs) can further degrade collagen and elastin in the extracellular matrix (ECM), thus playing a key role in skin aging.

[0129] Therefore, it is understandable that regulation of the AP-1 pathway can also protect collagen by controlling the expression of matrix metalloproteinases.

[0130] Accordingly, in another possible way, the present application embodiment found that oxanin and oxanin-containing compositions can also be used to inhibit the expression of AP-1 in photodamaged skin, thereby reducing the damage of MMPs to collagen. It is understandable that compositions containing oxanin, such as the aforementioned collagen fiber protectors for photodamaged skin, especially matrix metalloproteinase expression inhibitors, also have the function of inhibiting the expression of AP-1 in photodamaged skin, and can be used as AP-1 expression inhibitors for photodamaged skin. Thus, the present application embodiment provides a use of oxanin in the preparation of an AP-1 expression inhibitor for photodamaged skin. c-Fos belongs to an immediate early gene (IEG), which is a nuclear protein encoded by an early response gene that can be enriched and expressed in neurons. When neurons are stimulated or activated, the c-Fos gene will be rapidly induced to express, so it can be used as a marker for neuronal activation. By detecting the expression level of c-Fos, the activation state of neurons can be understood, and then the excitability of neurons, synaptic transmission, and the occurrence and development of neuropsychiatric diseases can be studied. Based on the above characteristics, many types of studies have successfully associated many specific behaviors with specific brain areas, which also makes c-Fos a very popular marker of neural activity.

[0131] Therefore, in another possible manner, okanin and compositions containing okanin can also be used to inhibit the expression of c-FOS in photodamaged skin, thereby inhibiting the expression of AP-1, and further reducing the damage of MMPs to collagen. It can be understood that compositions containing okanin, such as the aforementioned collagen fiber protectors for photodamaged skin, AP-1 expression inhibitors, etc., also have the function of inhibiting the expression of c-FOS in photodamaged skin, and can be used as c-FOS expression inhibitors for photodamaged skin. Thus, an embodiment of the present application provides a use of okanin in the preparation of a c-FOS expression inhibitor for photodamaged skin.

[0132] c-jun is a proto-oncogene that can bind to the promoters of many genes and participate in the regulation of gene transcription. Its protein encoding product can form heterodimers with other members of the AP-1 family and specifically bind to the DNA regions of certain genes to regulate the transcriptional activity of downstream genes.

[0133] Therefore, in another possible manner, okanin and compositions containing okanin can also be used to inhibit the expression of c-JUN in photodamaged skin, thereby inhibiting the expression of AP-1, and further reducing the damage of MMPs to collagen. It can be understood that compositions containing okanin, such as the aforementioned collagen fiber protectors for photodamaged skin, AP-1 expression inhibitors, etc., also have the function of inhibiting the expression of c-JUN in photodamaged skin, and can be used as c-JUN expression inhibitors for photodamaged skin. Thus, an embodiment of the present application provides a use of okanin in the preparation of a c-JUN expression inhibitor for photodamaged skin.

[0134] <The use of okanin in protecting collagen by regulating the MAPK pathway>

[0135] The MAPK (mitogen-activated protein kinase) pathway is an important factor affecting the expression of AP-1 in the skin. When MAPK is activated, it promotes the expression of AP-1, a dimer composed of c-Fos and c-Jun, and then destroys collagen through MMPs.

[0136] Based on this, the present application examples have found through research that okanin and compositions containing okanin can also be used to inhibit the expression of MAPK, thereby inhibiting the expression of AP-1, and then inhibiting the expression of MMPs, avoiding the destruction of collagen. It can be understood that compositions containing okanin, such as the aforementioned collagen fiber protectors for photodamaged skin, matrix metalloproteinase expression inhibitors, AP-1 expression inhibitors, etc., also have the function of inhibiting the expression of MAPK in photodamaged skin, and can be used as MAPK expression inhibitors for photodamaged skin.

[0137] Therefore, an embodiment of the present application also provides a use of okanin in the preparation of a MAPK expression inhibitor for photodamaged skin, which can protect collagen and photodamaged skin by regulating the MAPK pathway.

[0138] The signaling pathways of the MAPK family mainly include four pathways: extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK) / stress-activated protein kinase (SAPK), P38, and ERK5 / BMK1. ERK, JNK, P38, and ERK5 / BMK1 can be activated by different stimuli to form different transduction pathways, activate different transcription factors, and activate the MAPK pathway to mediate different biological effects.

[0139] In one possible manner, when the skin is damaged by light (eg, irradiated by UVB), the phosphorylation levels of JNK, p38, and ERK increase, leading to the activation of MAPK. The phosphorylation levels of JNK, p38, and ERK can be used as a marker for the activation state of MAPK.

[0140] JNK (c-Jun N-terminal kinase), also known as stress-activated protein kinase (SAPK), is another subclass of the MAPK signaling pathway in mammalian cells. In one possible manner, okanin and compositions containing okanin can also be used to reduce the phosphorylation level of JNK in the skin, inhibit the expression of JNK in photodamaged skin, reverse the abnormal expression of the MAPK pathway caused by UVB, and thereby reduce the damage of MMPs to collagen, thereby protecting the skin. It is understandable that compositions containing okanin, such as the aforementioned collagen fiber protectors for photodamaged skin, MAPK expression inhibitors, etc., also have the function of inhibiting the expression of JNK in photodamaged skin, and can be used as JNK expression inhibitors for photodamaged skin. Therefore, an embodiment of the present application provides a use of okanin in the preparation of a JNK expression inhibitor for photodamaged skin.

[0141] p38 refers to p38 protein kinase, which is also one of the subclasses of MAPKs. Its properties are similar to JNK, and it belongs to the same stress-activated protein kinase. In another possible way, okanin and compositions containing okanin can also be used to reduce the phosphorylation level of p38 in the skin, inhibit the expression of p38 in photodamaged skin, reverse the abnormal expression of the MAPK pathway caused by UVB, and thereby reduce the damage of MMPs to collagen. It can be understood that compositions containing okanin, such as the aforementioned collagen fiber protectors for photodamaged skin, MAPK expression inhibitors, etc., also have the function of inhibiting the expression of p38 in photodamaged skin, and can be used as p38 expression inhibitors for photodamaged skin. Therefore, an embodiment of the present application provides a use of okanin in the preparation of a p38 expression inhibitor for photodamaged skin.

[0142] ERK (abbreviation of extracellular regulated protein kinases, referring to extracellular regulated protein kinases) plays an extremely important role in the mitogen-activated protein kinase (MAPK) signal transduction pathway in the signal network. In another possible way, okanin and compositions containing okanin can also be used to reduce the phosphorylation level of ERK in the skin, inhibit the expression of ERK in photodamaged skin, reverse the abnormal expression of the MAPK pathway caused by UVB, and thereby reduce the damage of MMPs to collagen. It can be understood that compositions containing okanin, such as the aforementioned collagen fiber protectors for photodamaged skin, MAPK expression inhibitors, etc., also have the function of inhibiting the expression of ERK in photodamaged skin, and can be used as ERK expression inhibitors for photodamaged skin. Therefore, an embodiment of the present application provides a use of okanin in the preparation of an ERK expression inhibitor for photodamaged skin.

[0143] <Preparation of Okanin>

[0144] Okanin has the structure shown in the following formula (1):

[0145] Formula (1):

[0146] Okanin can be purchased commercially or prepared / extracted by oneself, and the extraction method can be a conventional method in the art or some specific method.

[0147] As an example, okanin may be extracted by a method comprising the following steps:

[0148] The dried snow chrysanthemum powder was divided into four 5L conical flasks, methanol was added at a volume ratio of 3:1 (methanol: powder), and the mixture was fully stirred and extracted for 24 hours. The filtrate was filtered and collected with a Buchner funnel, and the operation was repeated until the filtrate became clear. The filtrates were combined and concentrated under reduced pressure to obtain the snow chrysanthemum crude extract.

[0149] The crude extract of snow chrysanthemum was dissolved in water and then passed through a macroporous resin HP-20 adsorption column for preliminary separation and purification to remove sugar from the crude extract. The extract was then separated by gradient elution with water-anhydrous ethanol (volume ratio of 100:0, 50:50, 0:100), with each gradient being 5 column volumes. The eluted components were concentrated under reduced pressure to obtain the Kunlun snow chrysanthemum sugar-free crude extract, and the extract was eluted with the eluent being used as the eluent. The eluates were collected, combined, and concentrated under reduced pressure to obtain the snow chrysanthemum methanol extract.

[0150] The methanol extract of snow chrysanthemum was mixed with thin layer chromatography silica gel H, separated and purified by vacuum column, and separated by gradient elution of acetone: petroleum ether (volume ratio of 0:100, 20:80, 40:60, 80:20, 100:0), each gradient was 3 column volumes, the eluent was collected and concentrated under reduced pressure, and 17 bottles of products were obtained by TLC plate analysis: Fr.1 to Fr.17, each bottle 0.88 column volume. The product Fr.8 was passed through a gel column (Sephadex LH-20) and eluted with a CHCl3-MeOH mixture (volume ratio of 1:1) to obtain a pure compound, which was identified as Okanin by LC-MS and NMR.

[0151] <Use of Okanin>

[0152] Okanin can be used directly or prepared with other ingredients (such as water, acid, etc.) into a new substance for use.

[0153] The okanine-containing substances or products provided according to the embodiments of the present invention can be prepared and used in the form of external preparations (such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols), oral liquids, sterile injections, etc.

[0154] Optionally, the okanine-containing substance can be formulated into preparations in different forms such as creams, gels, patches, sprays, ointments, plasters, lotions, liniments, pastes or dressings.

[0155] Optionally, the carrier, excipient and diluent that may be included in the okanin-containing substance may be a compound containing at least one of the following: lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil.

[0156] Okanin can be used in different fields, such as in medicine, cosmetics, biofunctional materials and functional food materials.

[0157] <Composition containing okanine>

[0158] According to the uses of oxanthene in the aforementioned embodiments, the embodiments of the present application also provide a composition containing oxanthene, including oxanthene.

[0159] Optionally, the mass content of okanin is 0.01-5%, preferably 1-5%.

[0160] Optionally, the composition containing okanin is used as a collagen fiber protector for photodamaged skin. The collagen fiber protector for photodamaged skin has the function of protecting collagen fibers, thereby effectively repairing skin damage.

[0161] Optionally, the collagen fiber protector for photo-damaged skin is a collagen protector for photo-damaged skin, which protects collagen fibers by protecting collagen.

[0162] Optionally, the collagen protector for photodamaged skin acts as a collagen synthesis promoter for photodamaged skin to protect the collagen and collagen fibers of the photodamaged skin.

[0163] Optionally, the collagen protector of photo-damaged skin acts as a matrix metalloproteinase inhibitor of photo-damaged skin to protect the collagen and collagen fibers of photo-damaged skin.

[0164] Optionally, the collagen synthesis promoter for photodamaged skin serves as at least one of a promoter for mRNA expression of collagen genes for photodamaged skin and a promoter for regulating collagen synthesis in photodamaged skin based on the TGF-β / Smad pathway to promote collagen synthesis in photodamaged skin.

[0165] Optionally, the collagen gene includes at least one of COL1A1, COL3A1, COL6A1, and COL7A1.

[0166] Optionally, the mRNA expression promoter of a collagen gene of photodamaged skin is an mRNA expression promoter of at least one of type I collagen, type III collagen, type V collagen, type VI collagen, and type VII collagen.

[0167] Optionally, the collagen synthesis promoter for photodamaged skin serves as at least one of a type I collagen synthesis promoter for photodamaged skin, a type III collagen synthesis promoter for photodamaged skin, a type V collagen synthesis promoter for photodamaged skin, a type VI collagen synthesis promoter for photodamaged skin, and a type VII collagen synthesis promoter for photodamaged skin; so as to promote collagen synthesis in photodamaged skin.

[0168] Optionally, the promoter for regulating collagen synthesis in photodamaged skin based on the TGF-β / Smad pathway is at least one of a TGF-β expression promoter, a Smad2 / 3 expression promoter, and a Smad7 expression inhibitor.

[0169] Optionally, the matrix metalloproteinase inhibitor for photodamaged skin is at least one of an MMP-1 expression inhibitor, an MMP-3 expression inhibitor, and an MMP-9 expression inhibitor.

[0170] Optionally, the matrix metalloproteinase inhibitor of photodamaged skin acts as an inhibitor of AP-1 expression in photodamaged skin.

[0171] Optionally, the inhibitor of AP-1 expression in photo-damaged skin serves as at least one of an inhibitor of c-FOS expression in photo-damaged skin and an inhibitor of c-JUN expression in photo-damaged skin.

[0172] Optionally, the inhibitor of AP-1 expression in photo-damaged skin serves as the inhibitor of MAPK expression in photo-damaged skin.

[0173] Optionally, the MAPK expression inhibitor of photo-damaged skin serves as at least one of a JNK expression inhibitor of photo-damaged skin, a p38 expression inhibitor of photo-damaged skin, and an ERK expression inhibitor of photo-damaged skin.

[0174] Optionally, the composition containing okanin further comprises a solvent. Optionally, the solvent comprises water.

[0175] Optionally, the okanin-containing composition further comprises at least one of glyceryl monostearate, stearic acid, liquid paraffin, white petrolatum, diester of lauryl sulfate and glycerin.

[0176] Optionally, the composition containing oxanthate is in the form of a cream, which is an oxanthate-containing cream.

[0177] <Experimental example>

[0178] Seven experimental groups will be set up below, and the mouse skin tissues to be tested in the seven experimental groups will be tested in multiple aspects in combination with Experimental Examples 1-4 to verify the uses of Okanin in various aspects.

[0179] In Experimental Example 1-4, the mouse skin tissue used can be obtained according to the following steps 1-3:

[0180] Step 1: Cultivation of experimental mice:

[0181] Mice were housed in the Experimental Animal Center of Nanjing Agricultural University (Nanjing, China) under a controlled light-dark cycle of 12 h light / 12 h dark, an ambient temperature of 25 °C, and a humidity of 50–60%.

[0182] Step 2: Experimental group settings:

[0183] The 42 mice cultured above were randomly divided into 7 experimental groups, with 6 mice in each group. The 7 experimental groups were: blank control group, UV non-administration group, negative control group, positive control group, low-dose group, medium-dose group and high-dose group.

[0184] Step 3: Obtaining mouse skin tissue:

[0185] The mice in the seven experimental groups were treated according to the experimental conditions shown in Table 1. Specifically, the mice in the six experimental groups other than the blank control group were placed in UVB irradiation cages for irradiation. The irradiation dose in the first week was 100 mJ / cm 2 , irradiation 5 times a week, and the radiation dose increases by 100mJ / cm each week thereafter. 2 , until the fourth week 400mJ / cm 2 The test period is 4 weeks and the total irradiation dose is 5000mJ / cm 2 . During the experiment, if erythema, blisters and erosions appear on the mouse skin, stop irradiation immediately for 2-3 days and wait until the symptoms disappear before continuing the operation. Before each UVB irradiation, each experimental group except the blank control group and UV group applied the drug to the back skin of the mouse according to the corresponding drug shown in Table 1. After administration, the mice were given enough space to move alone for 1 hour to allow the drug to fully penetrate and absorb, and then they were exposed to light. 12 hours after the last irradiation and drug application, the mice were killed by cervical dislocation. The back skin tissue was collected, the connective tissue and subcutaneous fat were peeled off, and they were quickly frozen with liquid nitrogen and stored at -80°C for later use, which was used as the mouse skin tissue to be tested in each experimental group in subsequent experiments.

[0186] Table 1. Experimental conditions

[0187] Whether to irradiate Whether to administer medication Blank control group (referred to as group C) No irradiation No medication UV non-drug group (abbreviated as UV group) UVB irradiation No medication Negative control group (referred to as N group) UVB irradiation Administration of medication, the drug is a cream without occannin and vitamin A Positive control group (P group) UVB irradiation Medication, the drug is a cream containing vitamin A Low-dose group (referred to as L group) UVB irradiation Administration: a cream containing 1% oxaline Medium dose group (referred to as M group) UVB irradiation Administration: A cream containing 2.5% oxaline High-dose group (H group) UVB irradiation Administration: a cream containing 5% oxaline

[0188] The cream formula corresponding to each experimental group in Table 1 can be found in Table 2.

[0189] Table 2. Cream formula

[0190]

[0191] <Experimental Example 1: Verification of the use of okanin to directly promote collagen synthesis>

[0192] Experimental Example 1 includes the following steps:

[0193] The mouse skin tissues of each experimental group were fixed with 10% paraformaldehyde, and then embedded in paraffin and sliced. The slices were then mounted and fixed on a slide, and the content and density of collagen in the epidermis and skin tissue were observed by HE and Masson trichrome staining. The stained slice images were analyzed using an inverted microscope.

[0194] Results of Experimental Example 1:

[0195] The results of Experimental Example 1 are shown in Figure 1-10 .

[0196] Notes on 1-4: Figure 1This is an image of a HE-stained section of mouse skin tissue in groups C, P, UV, N, L, and M; Figure 2 This is a HE-stained section image of the skin tissue of mice in group H; Figure 3 A comparative schematic diagram of the epidermal thickness of the mouse skin in each group; Figure 4 A comparative diagram of the dermal thickness of the mouse skin in each group. Note: (1) n = 4, which means 4 parallel experiments; (2) The scale bar in the figure is 200 μm; (3) The data in the figure are expressed as mean ± standard deviation; (4) The meaning of “#” and “*” in the figure can be understood as follows: Compared with the blank control group,

[0197] ####p<0.0001; compared with the UV group, *p<0.05, ***p<0.001, ****p<0.0001.

[0198] Notes on 5-10: Figure 5 A Masson-stained section image of mouse skin tissue in groups C, P, UV, N, L, and M; Figure 6 This is a Masson-stained section image of mouse skin tissue in groups L, M, and H; Figure 7 A comparative diagram of the collagen content (Collagen ratio) in the skin tissue of each group of mice; Figure 8 A schematic diagram showing the comparison of the content of collagen Ⅰ in the skin tissue of mice in each group; Fig. 9 A schematic diagram showing the comparison of the content of collagen III in the skin tissue of mice in each group; Fig.10 A comparative diagram of hydroxyproline (HYP) in the skin tissue of mice in each group; Figure 5-6 In the Masson-stained sections, the blue is collagen fiber and the red is muscle fiber. Note: (1) n = 4, which means 4 parallel experiments; (2) The scale bar in the figure is 200 μm; (3) The data in the figure are expressed as mean ± standard deviation; (4) The meaning of “#” and “*” in the figure can be understood as follows: Compared with the blank control group,

[0199] ###p<0.001, ####p<0.0001; *p<0.05, ****p<0.0001 compared with the UV group.

[0200] Result analysis of Experimental Example 1:

[0201] 1. About Figure 1-4Results analysis

[0202] like Figure 1-2 As shown in the following figure: (1) From the HE staining results, it can be seen that the epidermal structure of mice (Group C) that were not irradiated with UVB was normal, and the collagen fiber structure of the dermis was intact and evenly distributed; (2) In the UV group after UVB irradiation, the collagen fiber structure of the mouse skin was destroyed and damaged; (3) After treatment, the negative control group N did not recover significantly, while the collagen fibers of the mouse skin in the L, M and H groups treated with okanidin recovered well, among which the therapeutic effect of Group H was similar to that of the positive control group P.

[0203] Continue to see Figure 3-4 It can be found that after UVB irradiation, the mouse epidermis thickened from 26.48±2.40μm to 57.30±3.46μm, and the dermis thinned from 792.27±39.91μm to 407.51±42.16μm, which also shows that the skin and the collagen fiber structure therein are damaged. The epidermal thickness under low, medium and high doses of okanin treatment in the L, M and H groups were 56.43±2.70, 39.80±1.17 and 30.32±3.35μm, respectively, and the dermal thickness was 559.69±35.25, 668.25±84.18 and 679.29±63.31μm, respectively, which were better than the UV group. Among them, the high-dose group had a similar therapeutic effect to the positive control group. Therefore, for skin irradiated by UVB, the composition containing okanin has the effect of reducing the thickness of the epidermis and increasing the thickness of the dermis.

[0204] The above results indicate that Okanin can effectively protect the collagen fiber structure, reduce the damage of UVB to the back skin tissue of mice, and play a role in protecting the skin.

[0205] 2. About Figure 5-10 Results analysis

[0206] Combination Figure 5-6 It can be seen that the collagen fibers in the dorsal skin of mice in the blank control group were tightly organized, but after UVB irradiation, as shown in the UV group, the collagen fibers in the blue part of the skin tissue were greatly reduced, and some collagen fibers were disordered and broken, indicating that UVB irradiation destroyed the collagen fibers in the skin. Comparing the results of the N group and the P group, it can be found that the negative control group was basically the same as the UV group, and the collagen fibers did not recover significantly, but the collagen fibers in the positive control group recovered better. Continuing to combine the images of the L, M and H groups, it can be seen that after low, medium and high doses of okanin treatment, the collagen fibers were significantly restored and the content became more.

[0207] In addition, combined Figure 7It can be seen that the collagen in the blue part of the collagen fibers in the mouse skin tissue of the UV group was approximately reduced by 48.56%, while in the L, M and N groups after treatment with low, medium and high doses of okanamin, the collagen fibers were significantly restored, and the collagen content recovered to about (35.23±3.01)%, (41.37±2.36)% and (57.16±6.75)% respectively, which were better than the UV group, and the repair effect of the high-dose group was even better than that of the positive control group P.

[0208] Continue as Figure 8 and 9 As shown, by comparing group C and group UV, it can be found that UVB irradiation caused a significant decrease in the content of type I collagen and type III collagen, which decreased by about 38.26% and 38.37%, respectively; but in groups L, M and H, after treatment with okanidin, the collagen content was significantly restored, and the type I and type III collagen contents in the skin of mice in the high-dose group H increased by 87.45% and 33.71%, respectively.

[0209] The content of HYP in skin tissue has always been used as an indicator to evaluate the stage of skin aging. The content of HYP reflects the content of collagen in the collagen fibers in the dermis. Fig.10 Reflecting the effect of UVB irradiation on HYP, by comparing group C and group UV, it can be found that after exposure to UVB, the HYP content in the mouse skin decreased by 52.97%; while the application of okanin significantly increased the HYP content, with group M and group H increasing by 50.75% and 50.32%, respectively, which was similar to the positive control group.

[0210] The above results indicate that Okanin can effectively inhibit the degradation of collagen fibers and collagen in mouse skin caused by UVB irradiation, play a role in protecting collagen fibers and collagen, and effectively repair skin damage.

[0211] <Experimental Example 2: Verification of the use of okanin to directly promote collagen synthesis>

[0212] The following experimental example 2 uses the qRT-PCR method to test the effect of oxanin on the mRNA expression level of collagen synthesis genes in the skin, verifying the use of oxanin in promoting collagen synthesis.

[0213] Experimental Example 2 includes the following experimental steps:

[0214] The total RNA from the skin tissue of the mice in each group was extracted and purified using Trizol reagent as the sample for each group. In addition, the concentration of total RNA was measured using NanoOneDrop TMSpectrophotometer quantification; for collagen genes COL1A1, COL3A1, COL5A2, COL6A1 and COL7A1, target cDNA was synthesized using a cDNA synthesis kit, and reverse transcription polymerase chain reaction used specific forward and reverse primers (see Table 3); QuantStudio TM 5 Real-time fluorescence quantitative PCR system was used to perform qRT-PCR analysis on the collagen genes COL1A1, COL3A1, COL5A2, COL6A1 and COL7A1 in each group of samples. Each sample was tested three times, and the relative mRNA expression level was calculated using the ΔΔCt method and normalized to the mRNA level of the internal reference GADPH of each sample.

[0215] Table 3. Primers used in reverse transcriptase polymerase chain reaction

[0216]

[0217] Note: "F" in Table 3 refers to the forward primer, and "R" refers to the reverse primer.

[0218] Experimental results of Experimental Example 2:

[0219] The experimental results are detailed in Figure 11-15 . Figure 11-15 The relative mRNA expression levels (Relative mRNA expression) of COL1A1, COL2A1, COL5A2, COL6A1 and COL7A1 in each experimental group (C, P, UV, N, L, M and H groups) are shown respectively.

[0220] about Figure 11-15 Other notes: (1) The data in the figures are expressed as mean ± standard deviation; (2) The meanings of “#” and “*” in the figures can be understood as follows: compared with the blank control group, #p<0.05, ##p<0.01, ###p<0.001, ####p<0.0001; compared with the UV group, *p<0.05, **p<0.001, ***p<0.001, ****p<0.0001; (3) The meaning of the term “of Control”: refers to the comparison with the blank control group.

[0221] Result analysis of Experimental Example 2:

[0222] Compared with the blank control group (group C), the mRNA expressions of type I collagen α1 gene (COL1A1), type III collagen α1 gene (COL3A1), type V collagen α2 gene (COL5A2), type VI collagen α1 gene (COL6A1), and type VII collagen α1 gene (COL7A1) in the dorsal skin tissue of mice after UVB irradiation (as shown in the UV group) were significantly decreased (P<0.05).

[0223] However, in the L, M, and H groups treated with okanidin, the mRNA expression levels of type I collagen α1 gene (COL1A1), type III collagen α1 gene (COL3A1), type V collagen α2 gene (COL5A2), type VI collagen α1 gene (COL6A1), and type VII collagen α1 gene (COL7A1) were significantly increased compared with the UV group.

[0224] In addition, except for the best recovery effect of COL5A2 in the medium-dose group (expression increased by 367.86%), the mRNA expression of other collagen genes COL1A1, COL3A1, COL6A1, and COL7A1 were all upregulated best under high-dose okanin treatment, increasing by 64.75%, 126.78%, 179.73%, and 171.36%, respectively. This indicates that okanin basically reduces the inhibitory effect of UVB irradiation on collagen synthesis mRNA in a dose-dependent manner.

[0225] The above results show that okanin can directly promote the synthesis of collagen, thereby alleviating the loss of collagen during photoaging. This proves that okanin can directly upregulate the expression of various collagen synthesis-related genes to promote collagen synthesis, thereby enhancing the protection of photodamaged skin and its collagen fibers.

[0226] <Experimental Example 3: Verification of the use of okanin in regulating collagen synthesis via the TGF-β / Smad pathway>

[0227] The following Experimental Example 3 is used to test the regulation of collagen synthesis by Okanin through the TGF-β / Smad pathway, and verify the use of Okanin in promoting collagen synthesis from the perspective of the TGF-β / Smad pathway.

[0228] Experimental Example 3 includes the following experimental steps:

[0229] Frozen mouse skin tissues from each group were taken, placed in 2 mL centrifuge tubes and thawed on ice, and then 0.1 M (mol / L) HCl and stainless steel beads were added and homogenized twice with a vortex instrument (2 min / time), and then centrifuged at 15000 rpm / min for 10 min at 4°C. The tissue lysates were collected for Western blotting analysis.

[0230] 30 μg of protein from tissue lysate was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinyl difluoride (PVDF) membrane. 5% skim milk was dissolved in Tris-HCl (trishydroxymethylaminomethane hydrochloride) and TBST buffer (containing Tween20, Tween20 refers to polysorbate-20) as a blocking solution, and the above-mentioned proteins were blocked at 37°C for 1 hour. Then, after washing 4 times with TBST buffer, the proteins were incubated with specific primary antibodies (TGF-β, Smad7, Smad2 / 3). After the incubation, the proteins were washed 4 times with TBST buffer again, and hybridized with the corresponding horseradish peroxidase (HRP)-coupled secondary antibodies (goat anti-rabbit antibody diluted 1:1000), and the immunoreactive proteins were detected by chemiluminescent gel imaging. The relative density of the protein bands in each group was analyzed using a densitometer system (imageJ), and GADPH (human phosphoinositide dehydrogenase) was used as an internal reference to normalize the measured optical density values ​​to obtain the corresponding mRNA expression level (Relative mRNA expression).

[0231] Experimental results of Experimental Example 3:

[0232] The experimental results are as follows Fig.16 and 17 shown.

[0233] about Fig.16 and 17 Description: Fig.16 A schematic diagram of a protein band corresponding to TGF-β, Smads7 and Smads2 / 3 in the skin tissue of each group of mice. The relative density of the protein bands can reflect the relative protein content, and further reflect the mRNA expression level of TGF-β, Smads7 and Smads2 / 3; Fig.17 It is a schematic diagram of the relative mRNA expression levels (Relative mRNA expression) of TGF-β, Smads7 and Smads2 / 3 in the skin tissue of each group of mice; in addition, when the data are involved in the figure, they are determined in the form of mean ± standard deviation; the meaning of "#" and "*" in the figure can be understood as follows: compared with the blank control group, #p<0.05, ##p<0.01, ###p<0.001, ####p<0.0001; compared with the UV group, *p<0.05, **p<0.001, ***p<0.001.

[0234] It should be noted that, unless otherwise stated, in the examples of the present application, the term "vehicel" represents a negative control, and "Tretinoin" represents retinoic acid.

[0235] Result analysis of Experimental Example 3:

[0236] The TGF-β / Smad pathway is the main signal transduction pathway that regulates the expression of collagen synthesis genes. Skin tissue produces excessive ROS after ultraviolet irradiation, which leads to downregulation of TGF-β and Smad2 / 3 expression and upregulation of Smad7 expression, thereby disrupting collagen synthesis.

[0237] Compared with the unirradiated mice (C group), the expression levels of TGF-β and Smad2 / 3 phosphorylation in the skin of mice irradiated by UVB (UV group) decreased by 55.41% and 71.40%, respectively, and the expression level of Smad7 increased by 72.19%, indicating that the synthesis of collagen in mouse skin was damaged after UVB irradiation.

[0238] Compared with the UV group, after treatment with the cream containing oxanthene, the TGF-β expression level and Smad2 / 3 phosphorylation expression level of the mouse skin (L, M and H groups) were increased, and the Smad7 phosphorylation level also decreased, indicating that oxanthene can regulate the expression of collagen synthesis genes through the TGF-β / Smad pathway and protect collagen synthesis.

[0239] In addition, it is worth noting that after treatment with a cream containing 5% okanin, the TGF-β expression level and Smad2 / 3 phosphorylation expression level of mouse skin (group H) increased by 68.70% and 108.24%, respectively, and the Smad7 phosphorylation expression level decreased by 51.98%, which has returned to a level similar to that of the positive control group.

[0240] The above results indicate that okanidin can promote the synthesis of skin collagen, protect collagen fibers, and alleviate the symptoms of skin photoaging caused by UVB irradiation by regulating the TGF-β-Smad2 / 3 pathway.

[0241] <Experimental Example 4: Verification of the use of okanin in protecting collagen by regulating the MAPK pathway>

[0242] The following Experimental Example 4 is used to verify the use of okanin in protecting collagen by regulating the MAPK pathway.

[0243] Experimental Example 4 includes the following steps:

[0244] Frozen mouse skin tissues from each group were taken, placed in 2 mL centrifuge tubes and thawed on ice, 0.1 M HCl and stainless steel beads were added, and then homogenized twice with a vortex instrument (2 min / time), and then centrifuged at 15000 rpm / min for 10 min at 4°C, and the tissue lysates were collected for Western blotting analysis.

[0245] 30 μg of proteins in the tissue lysate were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinyl difluoride (PVDF) membrane.

[0246] 5% skim milk was dissolved in Tris-HCl and Tween20 (TBST) buffer as blocking solution, and the protein was blocked at 37°C for 1 h. Then, after washing with TBST for 4 times, the cells were incubated with specific primary antibodies (MMP-1, MMP-3, MMP-9, p-JNK, JNK, p-ERK, ERK, p-P38, P38). After the incubation, the proteins were washed with TBST for 4 times again, and then hybridized with the corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies (goat anti-rabbit antibody or goat anti-mouse IgG antibody diluted 1:1000), and the immunoreactive proteins were detected by chemiluminescent gel imaging.

[0247] The relative densities of the protein bands corresponding to p-JNK (p-JNK is the phosphorylated active form of JNK), JNK, p-ERK (p-ERK is the phosphorylated active form of ERK), ERK, p-P38 (p-P38 is the phosphorylated active form of P38), P38, MMP-1, MMP-3 and MMP-9 in the skin tissues of each group of mice were analyzed using a densitometer system (imageJ). The optical density values ​​were normalized using GADPH as an internal reference.

[0248] Experimental results of Experimental Example 4:

[0249] The experimental results are shown in Figure 18-23 .

[0250] about Figure 18-23 Description: Fig.18 A schematic diagram of a protein band corresponding to MMP-1, MMP-3 and MMP-9 in the skin tissue of mice in each group; Fig.19 A schematic diagram of the relative protein content (Relative protein expression) of MMP-1, MMP-3 and MMP-9 in the skin tissue of each group of mice; Fig. 20 A schematic diagram of a protein band corresponding to c-FOS and c-JUN in the skin tissue of mice in each group; Fig.21A schematic diagram of the relative protein expression of c-FOS and c-JUN in the skin tissue of each group of mice; Fig. 22 A schematic diagram of a protein band corresponding to p-JNK, JNK, p-ERK, ERK, p-P38, and P38 in the skin tissue of mice in each group; Fig.23 It is a schematic diagram of the relative protein content (Relative protein expression) of p-JNK, JNK, p-ERK, ERK, p-P38 and P38 in the skin tissue of each group of mice; in addition, when the data are involved in the figure, they are determined in the form of mean ± standard deviation; the meaning of "#" and "*" in the figure can be understood as follows: compared with the blank control group, ###p<0.001, ####p<0.0001; compared with the UV group, *p<0.05, **p<0.01, ****p<0.0001.

[0251] Result analysis of Experimental Example 4:

[0252] 1. According to Figure 18-19 It can be seen that:

[0253] Compared with the blank control group (group C), after UVB irradiation, the expression levels of MMP-1, MMP-3, and MMP-9 in the skin tissue of mice in the UV group were significantly upregulated (p < 0.0001). The upregulation of MMPs expression levels is very detrimental to collagen in the skin, which is consistent with the results of collagen damage in the previous experimental examples 1-3.

[0254] However, after treatment with oxanthate, the expression levels of MMP-1, MMP-3, and MMP-9 in mouse skin tissue decreased, as shown in the results of groups L, M, and H. This indicates that oxanthate can downregulate the expression of MMP-1, MMP-3, and MMP-9 in photodamaged skin and avoid the destruction of collagen.

[0255] Moreover, after treatment with 5% okanin, the expression levels of MMP-1, MMP-3, and MMP-9 were downregulated by 62.84%, 51.30%, and 54.72%, respectively, among which the expression level of MMP-1 returned to the blank control level, with significant efficacy.

[0256] 2. According to Figure 20-21 It can be seen that:

[0257] Comparison between the C group and the UV group showed that UVB irradiation of the mouse skin upregulated the expression levels of c-FOS and c-JUN in the skin tissue. The increase in the expression levels of these two factors will promote the expression of dimer AP-1, which will in turn have an adverse effect on collagen in photodamaged skin.

[0258] However, after treatment with oxanthate, the expression levels of c-FOS and c-JUN in mouse skin tissues have decreased. This indicates that oxanthate can inhibit the expression of c-FOS and c-JUN, thereby reversing the abnormal expression of AP-1 in photodamaged skin, and is beneficial to inhibiting the expression of MMPs, especially the expression of MMP-1, MMP-3, and MMP-9.

[0259] In particular, after treatment with 5% okanamin, the expression level of c-Fos decreased by 38.68%, returning to the same level as the blank control group, while the expression level of c-Jun decreased by 22.61%, returning to the same level as the positive control group.

[0260] 3. According to Figure 22-23 It can be seen that:

[0261] By comparing group C and group UV, it can be determined that after UVB irradiation of mouse skin, the phosphorylation levels of JNK, p38 and ERK in skin tissue were upregulated, which can further promote the activation of MAPK pathway.

[0262] By comparing the L, M, and H groups, it can be determined that after treatment with oxanthate, the phosphorylation levels of JNK, p38, and ERK in the mouse skin tissue have decreased, which shows that oxanthate can reverse the abnormal expression of MAPK, which is beneficial to inhibiting the expression of c-FOS and c-JUN, and protecting collagen, collagen fibers, and skin.

[0263] It is also worth noting that after treatment with 5% okanamin, the phosphorylation levels of JNK, p38 and ERK decreased by 24.20%, 51.58% and 32.57%, respectively, among which the phosphorylation level of p38 returned to the same level as the positive control group, which was beneficial to significantly reverse the abnormal expression of MAPK, with obvious efficacy.

[0264] 4. Summary

[0265] In general, after UVB irradiates the mouse skin, it activates the MAPK pathway by upregulating the phosphorylation levels of JNK, p38 and ERK in the skin tissue; the activation of the MAPK pathway further promotes the increase in the expression levels of c-Fos and c-Jun, thereby upregulating the expression of AP-1, a dimer composed of the above two; after the expression of AP-1 is upregulated, MMP-1, MMP-3, and MMP-9 are also upregulated, which in turn has an adverse effect on the collagen fibers and collagen in the skin.

[0266] However, after treatment with okanidin, the expression levels of JNK, p38, ERK, c-Fos, c-Jun, MMP-1, MMP-3, and MMP-9 all decreased, which is enough to show that okanidin can reverse the abnormal expression of MAPK and AP-1 pathways caused by UVB and effectively protect the skin from photodamage.

[0267] Although the embodiments of the present invention have been disclosed as above, they are not limited to the applications listed in the specification and the implementation modes, and they can be fully applied to various fields suitable for the present invention. For those familiar with the art, additional modifications can be easily implemented. Therefore, without departing from the general concept defined by the claims and the scope of equivalents, the present invention is not limited to the specific details and the illustrations shown and described herein.

Claims

1. Use of okanin in preparing collagen fiber protector for photodamaged skin.

2. The use according to claim 1, wherein the collagen fiber protector for photodamaged skin has the function of protecting collagen, so as to achieve the purpose of protecting collagen fibers; in, When the collagen fiber protector for photo-damaged skin has a function for protecting collagen, the collagen fiber protector for photo-damaged skin has at least one of a function for promoting collagen synthesis and a function for inhibiting the expression of matrix metalloproteinases to achieve the function of protecting collagen in photo-damaged skin.

3. The use according to claim 2, When the collagen fiber protector of photodamaged skin has a function for promoting collagen synthesis, in, The collagen fiber protector for photodamaged skin has at least one of a function for promoting mRNA expression of collagen genes in photodamaged skin and a function for promoting collagen synthesis in photodamaged skin based on the TGF-β / Smad pathway, so as to promote collagen synthesis in photodamaged skin; When the collagen fiber protector for photodamaged skin has the function of inhibiting the expression of matrix metalloproteinases, the collagen fiber protector for photodamaged skin has at least one of the functions of inhibiting the expression of MMP-1, inhibiting the expression of MMP-3 and inhibiting the expression of MMP-9 in photodamaged skin; wherein, When the collagen fiber protector for photodamaged skin has at least one of the functions of inhibiting the expression of MMP-1 in photodamaged skin, inhibiting the expression of MMP-3 in photodamaged skin, and inhibiting the expression of MMP-9 in photodamaged skin, the collagen fiber protector for photodamaged skin has the function of inhibiting the expression of AP-1 in photodamaged skin.

4. The use according to claim 3, wherein the collagen fiber protector for photodamaged skin has a function of promoting the mRNA expression of collagen genes in photodamaged skin, in, The collagen gene includes at least one of COL1A1, COL3A1, COL5A1, COL6A1, and COL7A1, or The collagen fiber protector for photodamaged skin has a function of promoting the mRNA expression of at least one collagen gene among type I collagen, type III collagen, type V collagen, type VI collagen and type VII collagen.

5. The use according to claim 3, When the collagen fiber protector for photodamaged skin has a function for promoting collagen synthesis of photodamaged skin based on the TGF-β / Smad pathway, the collagen fiber protector for photodamaged skin has at least one of the functions of promoting the expression of TGF-β, promoting the expression of Smad2 / 3, and inhibiting the expression of Smad7; When the collagen fiber protector for photodamaged skin has a function for inhibiting the expression of AP-1 in photodamaged skin, the collagen fiber protector for photodamaged skin has at least one of a function for inhibiting the expression of c-FOS in photodamaged skin and an function for inhibiting the expression of c-JUN in photodamaged skin.

6. The use according to claim 5, When the collagen fiber protector for photodamaged skin has at least one of the function of inhibiting the expression of c-FOS in photodamaged skin and inhibiting the expression of c-JUN in photodamaged skin, the collagen fiber protector for photodamaged skin has the function of inhibiting the expression of MAPK in photodamaged skin.

7. The use according to claim 6, when the collagen fiber protector for photodamaged skin has the function of inhibiting the expression of MAPK in photodamaged skin, in, The collagen fiber protector for photodamaged skin has a function of inhibiting at least one of JNK expression in photodamaged skin, p38 expression in photodamaged skin, and ERK expression in photodamaged skin.

8. The use according to claim 1, in, The mass content of okanin is 0.01-5%.

9. Photo-damages the collagen fibers that protect the skin. It is characterized in that The invention comprises okanin, wherein the mass content of the okanin is 1-5%.

10. Use of an occannin-containing composition as a protector of collagen fibers in photodamaged skin.